Below are the financial statements of Dr Reddy's Laboratories, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of INR | 2024 | 2023 |
|---|---|---|
| Income | — | — |
| Sales | 271,396a | 234,595a |
| Service income and license fees | 7,768a | 11,284a |
| Other operating income | 947a | 818a |
| Total revenue from operations | 280,111a | 246,697a |
| Other income | 8,943a | 10,555a |
| Total income | 289,054a | 257,252a |
| Expenses | — | — |
| Cost of materials consumed | -44,901a | -42,198a |
| Purchase of stock-in-trade | -43,991a | -33,670a |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade | -6,805a | -709a |
| Employee benefits expense | -50,301a | -46,466a |
| Depreciation and amortisation expense | -14,700a | -12,502a |
| Impairment of non-current assets | -3a | -699a |
| Finance costs | -1,711a | -1,428a |
| Other expenses | -68,389a | -59,465a |
| Total expenses | -217,191a | -197,137a |
| Profit before tax and share of equity accounted investees | 71,863a | 60,115a |
| Share of profit of equity accounted investees, net of tax | 147a | 370a |
| Profit before tax | 72,010a | 60,485a |
| Tax expense | — | — |
| Current tax | -19,459a | -8,144a |
| Deferred tax | -3,228a | -7,268a |
| Profit for the year | 55,779a | 45,073a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.